Aurore Perrot

1 month ago | nature.com | Philippe Moreau |Katja Weisel |Hartmut Goldschmidt |Saad Usmani |Robert Orlowski |Nizar Bahlis | +7 more

AbstractIn the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years).

Oct 20, 2024 | nature.com | Nizar Bahlis |Luciano Costa |Maria-Victoria Mateos |Ajay K. Nooka |Aurore Perrot |Alfred Garfall | +1 more

Dear Editor,The risk of infection in patients with multiple myeloma (MM) is high, particularly for those with relapsed/refractory MM (RRMM), who typically exhibit substantial immune dysfunction due to multiple prior therapies as well as MM itself [1, 2]. The recent COVID-19 pandemic had an impact on patients with MM compared with non-MM patients, including a higher risk of infection, a higher excess mortality rate, and decreased survival in 2020 compared with 2019 [3].

Sep 25, 2024 | nature.com | Maria-Victoria Mateos |Katja Weisel |Valerio De Stefano |Hartmut Goldschmidt |Laure Vincent |Aurore Perrot | +2 more

AbstractTreatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of LocoMMotion, the first prospective study of real-world clinical practice (RWCP) in triple-class exposed (TCE) patients with RRMM, with a median follow-up of 26.4 months (range, 0.1–35.0). Patients (N  =  248) had received median 4 prior LOT (range, 2–13) at enrollment.

Mar 14, 2023 | nature.com | Paul Richardson |Aurore Perrot |Joseph R. Mikhael |Thomas Martin |Meral Beksac |Ivan Spicka | +2 more

AbstractThe International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab–pomalidomide–dexamethasone vs. pomalidomide–dexamethasone) and IKEMA (isatuximab–carfilzomib–dexamethasone vs.